secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2024-06-13T23:59:59+00:00
Accession:  0000950170-24-073129
Event type: other
Sentiment:  neutral
Materiality: 0.05
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics annual meeting results: all director nominees elected, auditor ratified
--------------------------------------------------------------------------------

- Dominick Colangelo re-elected as Class II director with 47.1M votes for (99.8% of votes cast).
- Edward Mathers re-elected with 32.7M for; David Meeker re-elected with 33.6M for.
- Ernst & Young ratified as independent auditor for FY2024 with 54.0M for (99.9% of votes cast).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000095017024073129/0000950170-24-073129-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000095017024073129/trvi-20240613.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-073129

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer